Navigation Links
Hill-Rom Reports Second Quarter Financial Results
Date:5/4/2009

s a 5.6 to 9.5 percent reduction versus prior year. The prior revenue guidance range was $1.375 to $1.470 billion. Our GAAP loss per fully diluted share from continuing operations is expected to be in the range of $6.61 to $6.91, versus a prior earnings range of $0.66 to $1.05. Adjusted earnings per fully diluted share are now expected to be $0.85 to $1.15. The prior guidance range was $0.82 to $1.18. Financial guidance in tabular format is included in the attached schedule.

Hill-Rom Holdings, Inc. provides earnings per share guidance on an adjusted basis from continuing operations because the company's management believes that the presentation provides useful information to investors. This measure excludes strategic developments, special charges, the impact of significant litigation and impairment charges. Such items may be highly variable, difficult to predict and of a size that sometimes have substantial impact on the company's reported operations for a period. Often, quantification of such items is not feasible. Management uses these measures internally for planning, forecasting and evaluating the performance of the business, including evaluating results relative to employee performance compensation targets. Investors should consider non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP.

Conference Call Replay and Webcast

The company will sponsor a conference call and webcast for the investing public at 8 a.m. EDT, 7 a.m. CDT, on Tuesday, May 5, 2009. The webcast is available at http://ir.hill-rom.com/events.cfm or '/>"/>

SOURCE Hill-Rom Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Hill-Rom to Present at the Bank of America 2009 Health Care Conference
2. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast
3. JCR and Hill-Rom Name First Nurse Scholar-in-Residence
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
6. Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year
7. DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 First Quarter Earnings Webcast
9. Hill-Rom Reports First Quarter Revenue of $350 Million and Announces Further Actions to Address Challenging Economic Environment
10. JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program
11. Hill-Rom Announces First Quarter 2009 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cambridge Scientists Archive 500,000th Crystal Structure 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Super Jake Foundation Hosts 5th Annual Heroes Bash on Nov 14 to Benefit Pediatric Cancer Research 58863 1Super Jake Foundation Hosts 5th Annual Heroes Bash on Nov 14 to Benefit Pediatric Cancer Research 58863 2Affinion Partners with OptumHealth 28SM 29 Allies 58858 1Affinion Partners with OptumHealth 28SM 29 Allies 58858 2Affinion Partners with OptumHealth 28SM 29 Allies 58858 3SEC Closes Investigation of PharmaNet Development Group and Recommends No Action 14350 1